Floatz logo

Muromonab-Cd3

Hemoglobinuria, Paroxysmal Nocturnal (PNH)

St. Jude Children's Research Hospitalmonoclonal_antibodyPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Hemoglobinuria, Paroxysmal Nocturnal (PNH) cohort.

Asset / SponsorPhaseRating
Thiotepa
Fred Hutchinson Cancer Center
Phase 3BB
Cyclophosphamide
Roswell Park Cancer Institute
Phase 3BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
St. Jude Children's Research Hospital
Phase 3BB
Evomela
Roswell Park Cancer Institute
Phase 3BB

View all 22 →

Same molecule, other indications

Muromonab-Cd3 is also rated in:

acute lymphoblastic leukemiaDormant
BB
Indicative ·
69 / 100
View asset →
Myelodysplastic Syndrome (MDS)Dormant
BB
Indicative ·
69 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →